UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 12b-25

Commission File Number 000-55575

NOTIFICATION OF LATE FILING

(Check	One): [X] Form 10-K [] Form 20-F [] Form 11-K [] Form	orm 10-Q [] Form N-SAR [] Form N-CSR	
For	Period Ended: December 31, 2020		
[] Tra [] Tra [] Tra	Instition Report on Form 10-K Instition Report on Form 20-F Instition Report on Form 11-K Instition Report on Form 10-Q Instition Report on Form N-SAR		
For	Transition Period Ended:	-	
	Nothing in this form shall be constru	ed to imply that the Commission has verified any inform	nation contained herein.
If the no	otification relates to a portion of the filing checked above,	identify the Item(s) to which the notification relates:	
PART I	I - REGISTRANT INFORMATION		
Full Na	me of Registrant: Sigyn Therapeutics, Inc.		
Former	Name if Applicable:		
Address	of Principal Executive Office (Street and Number):		
		8880 Rio San Diego Drive Suite 800 San Diego, CA 92108	
PART I	II - RULE 12B-25(B) AND (C)		
	abject report could not be filed without unreasonable efforbox if appropriate.)	ort or expense and the registrant seeks relief pursuant to R	ule 12b-25(b), the following should be completed.
[X] ((a) The reasons described in reasonable detail in Part III of	of this form could not be eliminated without unreasonable ef	fort or expense;
[X] (filed on or before the fifteenth calendar day following	ion report on Form 10-K, Form 20-F, Form 11-K, Form N the prescribed due date; or the subject quarterly report or tron or before the fifth calendar day following the prescribed	ansition report on Form 10-Q or subject distribution
((c) The accountant's statement or other exhibit required b	y Rule 12b-25(c) has been attached if applicable.	
PART I	III – NARRATIVE		
State be time per		0-Q, 10-D, N-SAR, N-CSR, or the transition report or portion	on thereof, could not be filed within the prescribed
unexpec		December 31, 2020 cannot be filed within the prescribed formation required to be included in the Form 10-K. The sed due date.	
PART I	IV - OTHER INFORMATION		-
(1)	Name and telephone number of person to contact in regard to this notification:		
	Jolie Kahn	011-972	215-375-6646
	(Name)	(Area Code)	(Telephone Number)
(2)	Have all other periodic reports required under Section 1	13 or 15(d) of the Securities Exchange Act of 1934 or Section	on 30 of the Investment Company Act of 1940 during

the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

[] Yes [X] No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2

Sigyn Therapeutics, Inc.

(Name of Registrant as specified in charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: March 31, 2021 By: /s/ Jim Joyce

Name: Jim Joyce

Title: Chief Executive Officer

3